Cargando…

Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma

SIMPLE SUMMARY: Platinum-based chemotherapy is the first-line treatment for advanced urothelial cell carcinoma (aUCC). After first-line treatment, we previously showed that maintenance therapy with vinflunine improves progression-free survival. However, some patients are resistant to vinflunine and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Font, Albert, Ruiz de Porras, Vicenç, Valderrama, Begoña P., Ramirez, Jose Luis, Nonell, Lara, Virizuela, José Antonio, Anido, Urbano, González-del-Alba, Aránzazu, Lainez, Nuria, Llorente, Maria del Mar, Jiménez, Natalia, Mellado, Begoña, García-Donas, Jesus, Bellmunt, Joaquim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699401/ https://www.ncbi.nlm.nih.gov/pubmed/34944855 http://dx.doi.org/10.3390/cancers13246235

Ejemplares similares

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer
por: Bernardini, Alejandra, et al.
Publicado: (2022)

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)(†)
por: De Santis, M., et al.
Publicado: (2016)

Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma
por: Morel, Armand, et al.
Publicado: (2010)

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2016)

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
por: Holmsten, Karin, et al.
Publicado: (2017)

Vinflunine in the treatment of bladder cancer
por: Bachner, Mark, et al.
Publicado: (2008)

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
por: Puente, Javier, et al.
Publicado: (2020)

Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group
por: Pistamaltzian, Nikolaos, et al.
Publicado: (2016)

From Clinical Trials to the Front Line: Vinflunine for Treatment of Urothelial Cell Carcinoma at the National Cancer Institute of Naples
por: Facchini, Gaetano, et al.
Publicado: (2016)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)
por: Méndez-Vidal, María José, et al.
Publicado: (2023)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
por: Fradet, Y, et al.
Publicado: (2019)

Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
por: Médioni, Jacques, et al.
Publicado: (2016)

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment—A Retrospective Multicenter Analysis
por: Riedel, Felix, et al.
Publicado: (2022)

Stathmin Potentiates Vinflunine and Inhibits Paclitaxel Activity
por: Malesinski, Soazig, et al.
Publicado: (2015)

SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016)
por: Lázaro, M., et al.
Publicado: (2016)

Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma
por: Prior, Celia, et al.
Publicado: (2014)

Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience
por: Retz, Margitta, et al.
Publicado: (2015)

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy
por: Brousell, Steven C, et al.
Publicado: (2018)

Urothelial carcinoma management in elderly or unfit patients()
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
por: Passalacqua, Rodolfo, et al.
Publicado: (2017)

SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
por: González del Alba, A., et al.
Publicado: (2018)

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report
por: Bordi, Paola, et al.
Publicado: (2016)

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
por: Boll, Lilian Marie, et al.
Publicado: (2023)

Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells
por: Aparicio, Luis A, et al.
Publicado: (2014)

Adjuvant treatment in lung cancer
por: Valladares, Begoña Taboada, et al.
Publicado: (2021)

Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
por: Castellano, Daniel, et al.
Publicado: (2014)

Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine, in vitro
por: Simoens, Cindy, et al.
Publicado: (2008)

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023)

Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers
por: Ruiz de Porras, Vicenç, et al.
Publicado: (2023)

Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
por: Holwell, S E, et al.
Publicado: (2001)

Upper tract urothelial carcinoma: a different disease entity in terms of management
por: Leow, Jeffrey J, et al.
Publicado: (2017)

SEOM Clinical guidelines for the treatment of metastatic prostate cancer
por: Cassinello, J., et al.
Publicado: (2014)

Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development
por: Kruczynski, A, et al.
Publicado: (2002)

VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland
por: Hussain, Syed A., et al.
Publicado: (2017)

Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer
por: Bowden, Michaela, et al.
Publicado: (2020)

Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium
por: Schinzari, Giovanni, et al.
Publicado: (2018)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
por: Jiménez-Guerrero, Rocío, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_073nu93f4skdo00bdhsr6v4puf